TY - JOUR
T1 - Superior prognostic utility of gross and metabolic tumor volume compared to standardized uptake value using PET/CT in head and neck squamous cell carcinoma patients treated with intensity-modulated radiotherapy
AU - Romesser, Paul B.
AU - Qureshi, Muhammad M.
AU - Shah, Bhartesh A.
AU - Chatburn, Luke T.
AU - Jalisi, Scharukh
AU - Devaiah, Anand K.
AU - Subramaniam, Rathan M.
AU - Truong, Minh Tam
N1 - Funding Information:
Acknowledgments RMS was supported by a GERRAF fellowship and a career development award from the Boston University Radiology Associates.
PY - 2012/8
Y1 - 2012/8
N2 - Objective To compare the prognostic utility of the 2-[18F] fluoro-2-deoxy-D-glucose (FDG) maximum standardized uptake value (SUV max), primary gross tumor volume (GTV), and FDG metabolic tumor volume (MTV) for disease control and survival in patients with head and neck squamous cell carcinoma (HNSCC) undergoing intensitymodulated radiotherapy (IMRT). Methods Between 2007 and 2011, 41 HNSCC patients who underwent a staging positron emission tomography with computed tomography and definitive IMRT were identified. Local (LC), nodal (NC), distant (DC), and overall (OC) control, overall survival (OS), and diseasefree survival (DFS) were assessed using the Kaplan-Meier product-limit method. Results With a median follow-up of 24.2 months (range 2.7-56.3 months) local, nodal, and distant recurrences were recorded in 10, 5, and 7 patients, respectively. The median SUVmax, GTV, and MTV were 15.8, 22.2 cc, and 7.2 cc, respectively. SUVmax did not correlate with LC (p = 0.229) and OS (p = 0.661) when analyzed by median threshold. Patients with smaller GTVs (<22.2 cc) demonstrated improved 2-year actuarial LC rates of 100 versus 56.4 % (p = 0.001) and OS rates of 94.4 versus 65.9 % (p = 0.045). Similarly, a smaller MTV (<7.2 cc) correlated with improved 2-year actuarial LC rates of 100 versus 54.2 % (p<0.001) and OS rates of 94.7 versus 64.2 % (p = 0.04). Smaller GTV and MTV correlated with improved NC, DC, OC, and DFS, as well. Conclusion GTV and MTV demonstrate superior prognostic utility as compared to SUVmax, with larger tumor volumes correlating with inferior local control and overall survival in HNSCC patients treated with definitive IMRT.
AB - Objective To compare the prognostic utility of the 2-[18F] fluoro-2-deoxy-D-glucose (FDG) maximum standardized uptake value (SUV max), primary gross tumor volume (GTV), and FDG metabolic tumor volume (MTV) for disease control and survival in patients with head and neck squamous cell carcinoma (HNSCC) undergoing intensitymodulated radiotherapy (IMRT). Methods Between 2007 and 2011, 41 HNSCC patients who underwent a staging positron emission tomography with computed tomography and definitive IMRT were identified. Local (LC), nodal (NC), distant (DC), and overall (OC) control, overall survival (OS), and diseasefree survival (DFS) were assessed using the Kaplan-Meier product-limit method. Results With a median follow-up of 24.2 months (range 2.7-56.3 months) local, nodal, and distant recurrences were recorded in 10, 5, and 7 patients, respectively. The median SUVmax, GTV, and MTV were 15.8, 22.2 cc, and 7.2 cc, respectively. SUVmax did not correlate with LC (p = 0.229) and OS (p = 0.661) when analyzed by median threshold. Patients with smaller GTVs (<22.2 cc) demonstrated improved 2-year actuarial LC rates of 100 versus 56.4 % (p = 0.001) and OS rates of 94.4 versus 65.9 % (p = 0.045). Similarly, a smaller MTV (<7.2 cc) correlated with improved 2-year actuarial LC rates of 100 versus 54.2 % (p<0.001) and OS rates of 94.7 versus 64.2 % (p = 0.04). Smaller GTV and MTV correlated with improved NC, DC, OC, and DFS, as well. Conclusion GTV and MTV demonstrate superior prognostic utility as compared to SUVmax, with larger tumor volumes correlating with inferior local control and overall survival in HNSCC patients treated with definitive IMRT.
KW - Gross tumor volume (GTV)
KW - Head and neck cancer
KW - Intensity-modulated radiotherapy (IMRT)
KW - Metabolic tumor volume (MTV)
KW - PET/CT
KW - Standardized uptake value (SUV)
UR - http://www.scopus.com/inward/record.url?scp=84866729977&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84866729977&partnerID=8YFLogxK
U2 - 10.1007/s12149-012-0604-5
DO - 10.1007/s12149-012-0604-5
M3 - Article
C2 - 22610386
AN - SCOPUS:84866729977
SN - 0914-7187
VL - 26
SP - 527
EP - 534
JO - Annals of Nuclear Medicine
JF - Annals of Nuclear Medicine
IS - 7
ER -